Apyx Medical Corp. (APYX) Tops Q4 EPS by 7c, Revenues Beat; Offers FY21 Revenues Guidance Below Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- S&P 500, Dow rise on Mideast deal hopes, SpaceX's historic debut
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil nears two-month lows on reports of imminent US-Iran peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Wall St set to gain on tech rebound, Middle East in focus
Apyx Medical Corporation Reports Fourth Quarter and Full Year 2020 Financial Results; Introduces Full Year 2021 Financial Outlook
March 31, 2021 7:00 AM EDTAdvanced Energy Sales increased 44% year-over-year in Q4
CLEARWATER, Fla.--(BUSINESS WIRE)-- Apyx Medical Corporation (NASDAQ: APYX) (the Company), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today reported financial results for its fourth quarter and full year ended December 31, 2020, and introduced financial expectations for the full year ending December 31, 2021.
Fourth Quarter 2020 Financial Summary:
Total revenue of $11.5 million, up 36.8%... More